GeneDx Holdings

GeneDx Holdings EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of GeneDx Holdings (WGS) as of Oct 16, 2026 is -3.26 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -11.83 % — a change of -72.42% (higher).

EBIT/Assets

-3.26 %

YoY

-72.42%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of GeneDx Holdings is 2025 -3.26 % . Operating Income to Assets Ratio (EBIT/Assets) of GeneDx Holdings was 2024 -11.83 % . It decreases by -72.42% higher compared to the previous year.

The GeneDx Holdings EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2020
-96.17 USD
Jan 1, 2021
-80.52 USD
Jan 1, 2022
-122.45 USD
Jan 1, 2023
-43.13 USD
Jan 1, 2024
-11.83 USD
Jan 1, 2025
-3.26 USD
The GeneDx Holdings EBIT/Assets history
YEAREBIT/AssetsYoY
-3.26 %-72.42%
-11.83 %-72.58%
-43.13 %-64.78%
-122.45 %+52.07%
-80.52 %-16.27%
-96.17 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GeneDx Holdings Stock analysis

What does GeneDx Holdings do? GeneDx Holdings Corp, trading under the ticker WGS, is a health care company headquartered in Stamford, Connecticut. The company went public on September 4, 2020, and currently employs 1,300 people. Its primary focus is delivering health intelligence through genetic diagnostics and data-driven insights. GeneDx offers diagnostic services primarily for pediatric and rare diseases, utilizing whole exome and genome sequencing technologies. The company processes DNA-containing samples through integrated laboratory and informatics systems to analyze genetic variations and provide reports to clinicians and patients. It also provides screening solutions and information services related to genetic diagnostics. The company operates through two segments: GeneDx and Legacy Sema4. The GeneDx segment focuses on pediatric and rare disease diagnostics, while the Legacy Sema4 segment provides reproductive and women’s health diagnostics, as well as somatic oncology testing and screening products. GeneDx Holdings Corp's website is sema4.com, though the company's operations and branding have evolved since its IPO. The company aims to inform diagnosis, guide treatment decisions, and support drug discovery through its genetic data analysis capabilities. GeneDx Holdings is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GeneDx Holdings stock

Operating Income to Assets Ratio (EBIT/Assets) of GeneDx Holdings is -3.26 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of GeneDx Holdings changed from -11.83 % to -3.26 %, representing a -72.42% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) GeneDx Holdings since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s GeneDx Holdings with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — GeneDx Holdings

All Key Metrics — GeneDx Holdings